RE:RE:RE:RE:I am almost convinced there's been a pushIn my opinion anyone attending ASCO that would be interested in buying TLT stock would spend 10 to 50 hours reading Phase 1 & 2 clinical data from the beginning to now. They will look at all NRs to get a "feel" of the company, remember those that attend are looking for advancements in this field so professional curiosity will be at work. If some are blown away they may seek investing advice before their purchase. We shouldn't assume they have knowledge in the investment arena, so its my opinion we could see a sporadic bump in the next few weeks..